Composition for prophylaxis or treatment of urinary system infection and method thereof

Abstract

The present invention relates to a composition for prophylaxis or treatment of urinary system infection, comprising a matrix metalloproteinase inhibitor. The present invention also relates to a method for prophylaxis or treatment of urinary system infection, comprising administering to a patient in need of such treatment an effective amount of composition comprising a matrix metalloproteinase inhibitor.

1 . A composition for prophylaxis of urethritis or cystitis, comprising a matrix metalloproteinase inhibitor. 
   
   
       2 . The composition of  claim 1 , wherein the matrix metalloproteinase inhibitor is selected from the group consisting of  Zizyphus jujuba, Malva sylvestris, Opuntia Streptacantha, Cinnamomi Cortex, Hippophae rhamnoides, Panax ginseng, Eriobotrya japonica, Citrus depressa  Hayata,  Nelumbo nucifera, Mosla chinensis , Fructus schisandrae,  Dalbergia odorfera, Smilax glabra , kale and their extracts. 
   
   
       3 . The composition of  claim 1 , wherein the matrix metalloproteinase inhibitor is selected from the group consisting of inhibitors of MMP-2 and MMP-9. 
   
   
       4 . The composition of  claim 1 , which further comprises at least one component selected from the group consisting of a macrophage function modulator, a pathogen isolator, and a urine pH stabilizer. 
   
   
       5 . The composition of  claim 4 , wherein the macrophage function modulator is able to activate the activity of calcineurin enzyme. 
   
   
       6 . The composition of  claim 4 , wherein the macrophage function modulator is selected from the group consisting of  Lonicera japonica  Thunb.,  Cordeceps sinensis , Sophorae Radix,  Hippophae rhamnoides , Flos Lonicerae, Pulsatillae Radix, extract of the dried leaf of  Camellia sinensis  (L.) C. Kuntze,  Ganoderma lucidum, Gynostemma pentaphyllum, Cynara Scolymus  L, Thyme, Fructus Schisandrae,  Prunellae spica, Lophatheri spica, Coptis Chinensis  Franchet, Dandelion ( Taraxacum officinale  F. Weber ex Wiggers), Portulacae Herba, Gardeniae Fructus, Sophora subprostrata Radix,  Houttuynia cordata  Thum,  Forsythia suspense  (Thum) Vahl,  Smilax glabra  and  Coptis groenlandica  Salisb. 
   
   
       7 . The composition of  claim 4 , wherein the pathogen isolator is selected from the group consisting of cranberry, cloudberry, raspberry, strawberry, bilberry,  Hippophae rhamnoides, Vitis vinifera  L.,  Hibiscus sabdariffa  L., grape seeds and the extract thereof. 
   
   
       8 . The composition of  claim 4 , wherein the urine pH stabilizer is selected from the group consisting of glycolic acid, gallic acid, ellagic acid, vanillic acid, citric acid, malic acid, tartaric acid, lactic acid, and vitamin C. 
   
   
       9 . The composition of  claim 4 , which comprises a macrophage function modulator. 
   
   
       10 . The composition of  claim 9 , wherein ratio of weight percent of the matrix metalloproteinase inhibitor to the macrophage function modulator is between 10:1 and 1:5. 
   
   
       11 . The composition of  claim 1 , which contains pharmaceutically acceptable excipients, carriers or diluents. 
   
   
       12 . A method for prophylaxis of urethritis or cystitis, comprising administering to a patient in need of said prophylaxis an effective amount of a matrix metalloproteinase inhibitor. 
   
   
       13 . The method of  claim 12 , wherein the matrix metalloproteinase inhibitor is selected from the group consisting of  Zizyphus jujuba, Malva sylvestris, Opuntia Streptacantha , Cinnamomi Cortex,  Hippophae rhamnoides, Panax ginseng, Eriobotrya japonica, Citrus depressa  Hayata,  Nelumbo nucifera, Mosla chinensis , Fructus schisandrae,  Dalbergia odorfera, Smilax glabra , kale and their extracts. 
   
   
       14 . The method of  claim 12 , wherein the matrix metalloproteinase inhibitor is selected from the group consisting of inhibitors of MMP-2 and MMP-9. 
   
   
       15 . The method of  claim 12 , which comprises administering additional component selected from the group consisting of a macrophage function modulator, a pathogen isolator, and a urine pH stabilizer. 
   
   
       16 . The method of  claim 15 , wherein the macrophage function modulator is able to activate the activity of calcineurin enzyme. 
   
   
       17 . The method of  claim 15 , wherein the macrophage function modulator is selected from the group consisting of  Lonicera japonica  Thunb.,  Cordeceps sinensis , Sophorae Radix,  Hippophae rhamnoides , Flos Lonicerae, Pulsatillae Radix, extract of the dried leaf of  Camellia sinensis  (L.) C. Kuntze,  Ganoderma lucidum, Gynostemma pentaphyllum, Cynara Scolymus  L, Thyme, Fructus Schisandrae,  Prunellae spica, Lophatheri spica, Coptis Chinensis  Franchet, Dandelion ( Taraxacum officinale  F. Weber ex Wiggers),  Portulacae Herba, Gardeniae  Fructus, Sophora subprostrata Radix,  Houttuynia cordata  Thum,  Forsythia suspense  (Thum) Vahl,  Smilax glabra  and  Coptis groenlandica  Salisb. 
   
   
       18 . The method of  claim 15 , wherein the pathogen isolator is selected from the group consisting of cranberry, cloudberry, raspberry, strawberry,  Hippophae rhamnoides, Vitis vinifera  L.,  Hibiscus sabdariffa  L., grape seeds and the extract thereof. 
   
   
       19 . The method of  claim 15 , wherein the urine pH stabilizer is selected from the group consisting of glycolic acid, gallic acid, ellagic acid, vanillic acid, citric acid, malic acid, tartaric acid, lactic acid, and vitamin C.